T cells with CD19/CD3 chimeric antigen receptors (CAR-T) have been shown to induce high remission rate (90 % CR in refractory ALL), and can expand 1000 times in vivo [77–80]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.